Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Biogen paid Ionis a US $ 60 million one-time upfront payment
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
When used alongside rehabilitative exercise, this device may offer benefit to those who have lost function in their upper limbs due to ischemic stroke
Subscribe To Our Newsletter & Stay Updated
